Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered immune cells take on pancreatic cancer in first human trial

NCT ID NCT07153289

Disease control Sponsor: University Hospital Tuebingen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase trial tests a new treatment called CD318-CAR-T cells for people with advanced pancreatic cancer that has worsened after standard therapy. The therapy uses a patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The study aims to check if the treatment is safe and feasible, and to get an early look at whether it can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CD318-targeted CAR-T cells (a type of immune cell therapy)
What this could lead to
If successful, this could point toward a new treatment option for advanced pancreatic cancer, a disease with very few effective therapies.
What could go wrong
This is a very early, first-in-human trial with only 38 participants. CAR-T cell therapy can cause severe side effects like cytokine release syndrome, and it is unknown if it will work against solid tumors like pancreatic cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 38 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years at the time of informed consent * Histologically confirmed PDAC (metastatic or locally advanced, unresectable) * Measurable disease according to RECIST v1.1 * Disease progression during or after at least one prior line of systemic standard therapy for advanced PDAC * CD318 expression in tumor tissue confirmed by central immunohistochemistry (IHC) * ECOG performance status of 0 or 1 * Adequate bone marrow, renal, and hepatic function as defined in the protocol * Life expectancy of at least 12 weeks * Willingness and ability to comply with study procedures and follow-up * Written informed consent obtained prior to any study-specific procedures- Exclusion Criteria: * Prior treatment with CAR T cells or other genetically modified cell therapies * Active uncontrolled infection, including active hepatitis B or C infection or HIV infection * Known symptomatic or untreated central nervous system (CNS) metastases * Clinically significant cardiovascular disease, including recent myocardial infarction (within 6 months), unstable angina, or uncontrolled arrhythmia * History of autoimmune disease requiring systemic immunosuppressive therapy * Current or recent (within 4 weeks) participation in another interventional clinical trial * Pregnant or breastfeeding women * Any condition that, in the opinion of the investigator, would interfere with the patients ability to comply with study requirements or would compromise safety

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Carcinoma, pancreatic ductal are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Carcinoma, pancreatic ductal Pancreatic neoplasms

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.